Market Intelligence, Clinical Progress, and High-Purity Reagents for Tuberous Sclerosis Complex and mTOR Pathway Modulator Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TSC2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TSC2 Recombinant Protein (Full-length / Domain-specific) High purity (>90%), Endotoxin controlled. Sequence Verified. Ideal for protein-protein interaction (PPI) and GAP assays. |
View TSC2 Products |
| Gene Delivery | TSC2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and phenotypic rescue assays. |
View TSC2 Products |
| Benchmark Ab | Anti-TSC2 Recombinant Antibody High-specificity positive control for Western Blot, IHC, and immunoprecipitation. |
View TSC2 Products |
| Validator | TSC2 siRNA Set Target-specific knockdown verification in cell-based functional assays. |
View TSC2 Products |
| Related Target A | TSC1 (Hamartin) Crucial binding partner forming the TSC1/2 complex; essential for regulatory stability. |
View TSC1 Products |
| Related Target B | Rheb (Ras Homolog Enriched in Brain) The direct downstream GTPase substrate of TSC2 GAP activity. |
View Rheb Products |
| Related Target C | mTOR Master kinase regulated by the TSC1/2-Rheb axis; key readout for TSC2 functional rescue. |
View mTOR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| TSC1/2 Complex Reconstitution | Co-expression compatible TSC1 and TSC2 recombinant proteins with verified sequence integrity. |
| Low Yield of Large Intracellular Proteins | Sf9/Baculovirus or HEK293 eukaryotic expression systems optimized for high molecular weight proteins. |
| Lack of Controls for Knockout/Rescue | Sequence-verified Lentivirus for expression rescue and verified siRNA sets for functional knockdown. |
| Nonspecific Antibody Binding | Recombinant monoclonal benchmark antibodies ensuring high specificity without batch-to-batch variation. |
Live TSC2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the TSC2 pathway is undergoing a major paradigm shift. Historically managed through systemic mTOR inhibitors (such as rapalogs), the next generation of drug discovery is moving toward gene replacement therapies (AAV-mediated TSC2 delivery), mRNA therapeutics, and allele-specific small molecules aimed at restoring TSC2 GAP activity or targeting synthetic lethal pathways in TSC2-deficient cells.
As clinical pipelines expand into gene therapy and precision oncology, robust cell-based assays that validate the restoration of the TSC1/TSC2 complex and the subsequent suppression of downstream Rheb-mTORC1 signaling have become the gold standard for preclinical evaluation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV) | Bridge Bio, Lexeo Therapeutics | Tuberous Sclerosis Complex (TSC), LAM | Functional rescue assay (Need TSC2 Lentivirus for cell model development) |
| Small Molecule (Synthetic Lethality) | Deciphera, Novartis | TSC2-mutant Solid Tumors | Selectivity screening (Need wild-type vs mutant TSC2 proteins) |
| mRNA Therapeutics | Moderna, Translate Bio | Monogenic Rare Diseases | Intracellular translation & activity assay (Need TSC2 benchmark antibodies) |